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Abstract 
Adverse drug reactions are among the most frequent side effects of synthetic and comple-
mentary alternative drugs and represent the premier causes of license revocations and acute 
liver failure. Drug-induced liver injury can resemble literally any other genuine liver disease 
and usually responds well to drug dechallenge. However, in some cases autoimmune-like 
hepatitis can evolve, requiring short- and sometimes long-term immunosuppression. Here, 
we present the hitherto first case of autoimmune-like hepatitis following treatment with 
zoledronic acid. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Bisphosphonates are the first-line treatment in women with postmenopausal osteopo-
rosis, with a well-documented benefit in the prevention of spontaneous fractures and im-
provement of bone density [1]. Severe adverse drug reactions are rare and the most com-
mon side effects include nausea, myalgia, and headaches. 
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Along with the widespread use of zoledronic acid (ZA), case reports describe drug-
induced liver injury (DILI) causally ascribed to its administration [2–4]. In all cases, acute 
hepatitis with markedly elevated aspartate aminotransferase, alanine aminotransferase,  
and gamma-glutamyl transpeptidase following ZA administration was noticed, which rapidly 
subsided upon cessation of treatment. Prolonged adverse hepatic reactions due to ZA not 
responding to dechallenge, including autoimmune hepatitis (AIH), have not been observed 
to date. 
Here, we present the case of a female patient who developed AIH after intravenous 
treatment with ZA requiring immunosuppressive treatment to reach stable remission. 
Case Report 
A 73-year-old female patient was referred to our outpatient liver clinic with fatigue, 
pruritus, generalized arthralgia, and acute hepatitis. The medical history had started 5 weeks 
prior to the first consultation with abdominal discomfort, nausea, diarrhea, and fever of 40°C 
for about 1 week, which had forced her to contact her general practitioner. Recently, the 
patient had been newly treated with ZA on one occasion for osteoporosis prior to the onset 
of her clinical symptoms. Apart from the short febrile episode, no further clinical signs of 
infection or malignancy were evident. 
Besides osteoporosis, the past medical history revealed symptoms compatible with irri-
table bowel syndrome. In addition, a platelet dysfunction termed storage pool deficiency had 
been established in 2009. The regularly prescribed medication was linaclotid for irritable 
bowel syndrome, and bisacodyl and Psyllium seed husks for chronic obstipation. Regular or 
harmful alcohol consumption as well as smoking was convincingly denied. Upon physical 
examination, no jaundice was recorded, but the patient complained about mild pruritus. 
Abdominal palpation was unremarkable with no pain or tenderness. No cardiovascular or 
neurological abnormalities were recorded. Abdominal ultrasound and computed tomogra-
phy revealed no explanation for the clinical picture. Laboratory results showed elevated 
aspartate aminotransferase at 349 U/L, alanine aminotransferase at 183 U/L, and gamma-
glutamyl transpeptidase at 639 U/L. Prior to the current symptoms, serum liver enzyme 
levels had been repeatedly found to be normal on routine tests. 
Serological testing for viral hepatitis, including anti-hepatitis A virus IgM, HBsAg, HBeAg, 
anti-HBs, anti-HBe, anti-HBc, hepatitis B virus DNA, anti-hepatitis C virus, hepatitis C virus 
RNA, anti-cytomegalovirus IgM, anti-Epstein-Barr virus IgM, anti-hepatitis E virus IgM/IgG, 
and human immunodeficiency virus, turned out negative. 
The titer of antinuclear antibodies was mildly elevated at 1:80, but the serum IgG level 
was within normal range (11.5 g/L). Other autoimmune markers, including anti-mitochon-
drial antibodies, liver-kidney-microsomal antibodies, and smooth muscle actin antibodies, 
were all found to be below the level of detection. 
In essence, the working diagnosis was acute DILI presenting with a predominantly cyto-
lytic enzyme pattern, i.e., hepatitis. Initially, liver enzymes showed a moderate decline to a 
plateau of persistent elevation and a sudden increase after several weeks (Fig. 1). This 
course together with persistent fatigue and nausea prompted us to perform a percutaneous 
liver biopsy, which showed features compatible with AIH such as lymphoplasmacellular 
infiltration, necrosis, and fibrous collapse (Fig. 2). 
Based on these findings, drug-induced AIH was assumed. According to the simplified  
diagnostic criteria for AIH set forth in the paper by Hennes et al. [5], the patient reached  
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5 points, which falls behind the definition of definite AIH (≥7 points), but the typical histolo-
gy of our patient was considered clinically decisive for starting therapy with 50 mg of pred-
nisolone daily. Following a rapid improvement both clinically and biochemically (Fig. 1), 
steroids were tapered at 10 weeks of treatment after biochemical remission. Four weeks 
after cessation of steroids, the patient showed again rising transaminases, indicating recur-
rence of hepatitis. Due to marked side effects of steroids during the first course of therapy, 
budesonide at 3 mg three times a day in combination with azathioprine was started, upon 
which the patient went into remission. However, she developed nausea and vomiting upon 
azathioprine and was switched to mycophenolate mofetil, upon which she stayed in remis-
sion until recently. 
Discussion 
We here present a case of AIH following the intake of ZA, a complication of bisphospho-
nates which has hitherto not been described. Our patient developed biochemical hepatitis as 
well as low-level autoantibodies and revealed typical features of autoimmune liver disease 
on histology. Treatment with steroids and mycophenolate mofetil induced full remission, but 
the patient required long-term immunosuppression. 
During the entire course of the incident, no eosinophilia, jaundice, or coagulopathy was 
observed, so according to a recent severity classification set forth by the Drug-Induce Liver 
Injury Network, the patient experienced a mild course of DILI, as there was no significant 
bilirubin elevation or coagulopathy [6]. 
DILI is frequent, and hepatitis in this context is a well-described biochemical pattern. In 
fact, DILI is the most frequent cause of drug withdrawal, and fulminant hepatitis following 
drugs is the most frequent cause of acute liver failure leading to liver transplantation [7]. 
While the majority of fulminant cases are related to paracetamol overdose, often with sui-
cidal intention, the remaining cases are mostly due to idiosyncratic drug reactions. The latter 
are unpredictable and dose-independent and may be related to either toxic or autoimmune 
pathophysiology. 
Regarding the latter, the underlying pathophysiology is believed to relate to a covalent 
binding of drug metabolite to membrane surface proteins of hepatocytes (commonly a phase 
I or phase II drug-metabolizing enzyme) to form neoantigens. Subsequent activation of CD8 
T lymphocytes with nonselective antigen receptors leads to a (transient or permanent) loss 
of self-tolerance and tissue injury [8]. 
DILI presenting with the biological and/or histological features of AIH is well described 
along with the intake of minocycline, alpha-methyldopa, or nitrofurantoin, but usually shows 
a chronic course and may progress to cirrhosis in rare instances [9]. Corticosteroid respon-
siveness is similar in drug-induced AIH and classical AIH; however, discontinuation of im-
munosuppression rarely precipitates relapses in the former [8], which regularly occur in the 
latter upon cessation of therapy [10]. This raises the question whether our patient had in 
fact true AIH unrelated to any medication, but absence of key criteria of AIH including auto-
antibodies and elevated IgG levels render this possibility rather unlikely. Simple hepatotox-
icity from ZA as previously described also appears to be less likely as the patient relapsed 
although ZA had been stopped 4 months earlier. 
The causality of the adverse hepatic reaction was classified according to the Council for 
International Organizations of Medical Sciences definitions for acute liver injury and reached 
a score of 8, which indicates a “probable causality” with the intake of a given medication, and 
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only falls short of a “definite causality” (>8) since the type of DILI, i.e., autoimmune-like reac-
tion, had not been hitherto described [11]. 
In conclusion, the presented incident appears to represent a rare case of AIH precipitat-
ed by the intake of ZA, requiring immunosuppressive therapy. Therefore, medical prescrib-
ers are advised to pay attention to DILI in patients treated with ZA and to consider autoim-
mune-like features as a possibility. 
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Fig. 1. Course of liver enzymes in a patient with acute hepatitis following treatment with zoledronic acid. 
Cessation of steroids after reaching normal liver enzyme levels resulted in a relapse of hepatitis. 
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Fig. 2. a Liver biopsy specimen showing severe hepatitis with centrilobular necrosis and fibrous collapse as 
well as formation of pseudorosettes (hematoxylin/eosin stain, ×100). b Immunohistochemistry stain of a 
liver biopsy specimen showing plasmacellular infiltration positive for CD38 antigen (×100). 
 
